Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yannick Allanore

Showing results (321-330 of 448) with videos related to

Pageof 45
Sort By:
The Lancet. Rheumatology|January 24, 2024
Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohortsSophie I E Liem, Maaike Boonstra, Saskia le Cessie, et al.
Journal of Internal Medicine|June 28, 2023
Mouth opening in systemic sclerosis: A longitudinal analysis from the French National Cohort StudyBenjamin Chaigne, Alexandre Bense, Christian Agard, et al.
Plos One|August 14, 2013
The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian populationRaphael Borie, Bruno Crestani, Philippe Dieude, et al.
Advances in Therapy|November 11, 2023
Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT StudyMarc Schmalzing, Herbert Kellner, Ayman Askari, et al.
Annals of the Rheumatic Diseases|December 21, 2012
Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational studyMuriel Elhai, Marine Meunier, Marco Matucci-Cerinic, et al.
Plos One|October 6, 2016
Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR StudyVeronika K Jaeger, Elina G Wirz, Yannick Allanore, et al.
Journal of Scleroderma and Related Disorders|January 8, 2025
Longitudinal association between nailfold capillaroscopy and incident interstitial lung disease: A EUSTAR database analysisArthiha Velauthapillai, Jeska K de Vries-Bouwstra, Joerg Henes, et al.
Arthritis and Rheumatism|April 12, 2011
C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: results from a large french cohort and meta-analysisBaptiste Coustet, Philippe Dieudé, Mickael Guedj, et al.
The Journal of Rheumatology|January 17, 2017
Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for ScreeningMaria-Grazia Lazzaroni, Ilaria Cavazzana, Enrico Colombo, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 15, 2017
Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic SclerosisJérôme Avouac, Christophe Guignabert, Anna Maria Hoffmann-Vold, et al.
Pageof 45

Showing results (321-330 of 448) with videos related to

Sort By:
Pageof 45
The Lancet. Rheumatology|January 24, 2024
Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohortsSophie I E Liem, Maaike Boonstra, Saskia le Cessie, et al.
Journal of Internal Medicine|June 28, 2023
Mouth opening in systemic sclerosis: A longitudinal analysis from the French National Cohort StudyBenjamin Chaigne, Alexandre Bense, Christian Agard, et al.
Plos One|August 14, 2013
The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian populationRaphael Borie, Bruno Crestani, Philippe Dieude, et al.
Advances in Therapy|November 11, 2023
Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT StudyMarc Schmalzing, Herbert Kellner, Ayman Askari, et al.
Annals of the Rheumatic Diseases|December 21, 2012
Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational studyMuriel Elhai, Marine Meunier, Marco Matucci-Cerinic, et al.
Plos One|October 6, 2016
Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR StudyVeronika K Jaeger, Elina G Wirz, Yannick Allanore, et al.
Journal of Scleroderma and Related Disorders|January 8, 2025
Longitudinal association between nailfold capillaroscopy and incident interstitial lung disease: A EUSTAR database analysisArthiha Velauthapillai, Jeska K de Vries-Bouwstra, Joerg Henes, et al.
Arthritis and Rheumatism|April 12, 2011
C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: results from a large french cohort and meta-analysisBaptiste Coustet, Philippe Dieudé, Mickael Guedj, et al.
The Journal of Rheumatology|January 17, 2017
Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for ScreeningMaria-Grazia Lazzaroni, Ilaria Cavazzana, Enrico Colombo, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 15, 2017
Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic SclerosisJérôme Avouac, Christophe Guignabert, Anna Maria Hoffmann-Vold, et al.
Pageof 45